These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 26571362)

  • 1. The safety of daclatasvir for the treatment of hepatitis C.
    Jafri SM; Gordon SC
    Expert Opin Drug Saf; 2015; 14(11):1787-97. PubMed ID: 26571362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection.
    Herbst DA; Reddy KR
    Expert Opin Investig Drugs; 2013 Oct; 22(10):1337-46. PubMed ID: 23931586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
    Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
    Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
    Manns M; Pol S; Jacobson IM; Marcellin P; Gordon SC; Peng CY; Chang TT; Everson GT; Heo J; Gerken G; Yoffe B; Towner WJ; Bourliere M; Metivier S; Chu CJ; Sievert W; Bronowicki JP; Thabut D; Lee YJ; Kao JH; McPhee F; Kopit J; Mendez P; Linaberry M; Hughes E; Noviello S;
    Lancet; 2014 Nov; 384(9954):1597-605. PubMed ID: 25078304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daclatasvir for the treatment of chronic hepatitis C.
    Degasperi E; Aghemo A; Colombo M
    Expert Opin Pharmacother; 2015; 16(17):2679-88. PubMed ID: 26549010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daclatasvir for the treatment of hepatitis C virus infection.
    Adler H; Lambert JS
    Expert Rev Gastroenterol Hepatol; 2014 Sep; 8(7):725-38. PubMed ID: 24882552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C.
    Esposito I; Marciano S; Trinks J
    Expert Opin Drug Metab Toxicol; 2018 Jun; 14(6):649-657. PubMed ID: 29855221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asunaprevir for hepatitis C: a safety evaluation.
    Gentile I; Zappulo E; Buonomo AR; Scotto R; Borgia G
    Expert Opin Drug Saf; 2015 Oct; 14(10):1631-46. PubMed ID: 26329454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C.
    Carrion AF; Martin P
    Expert Opin Drug Saf; 2016 Jun; 15(6):883-90. PubMed ID: 27091555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profile of alisporivir and its potential in the treatment of hepatitis C.
    Gallay PA; Lin K
    Drug Des Devel Ther; 2013; 7():105-15. PubMed ID: 23440335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in hepatitis C therapies.
    Mariño Z; Lens S; Gambato M; Forns X
    Expert Opin Pharmacother; 2015; 16(13):1929-43. PubMed ID: 26219918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study.
    Piroth L; Paniez H; Taburet AM; Vincent C; Rosenthal E; Lacombe K; Billaud E; Rey D; Zucman D; Bailly F; Bronowicki JP; Simony M; Diallo A; Izopet J; Aboulker JP; Meyer L; Molina JM;
    Clin Infect Dis; 2015 Sep; 61(5):817-25. PubMed ID: 25977266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current race in the development of DAAs (direct-acting antivirals) against HCV.
    De Clercq E
    Biochem Pharmacol; 2014 Jun; 89(4):441-52. PubMed ID: 24735613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of direct antiviral agents in the management of hepatitis C.
    El Kassas M; Elbaz T; Hafez E; Esmat G
    Expert Opin Drug Saf; 2016 Dec; 15(12):1643-1652. PubMed ID: 27661100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy for hepatitis C genotype 3: moving forward.
    Buti M; Llaneras J; Riveiro-Barciela M; Esteban R
    J Viral Hepat; 2015 Sep; 22(9):683-90. PubMed ID: 25967352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sofosbuvir as backbone of interferon free treatments.
    Bourlière M; Oules V; Ansaldi C; Adhoute X; Castellani P
    Dig Liver Dis; 2014 Dec; 46 Suppl 5():S212-20. PubMed ID: 25453869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing the face of hepatitis C management - the design and development of sofosbuvir.
    Noell BC; Besur SV; deLemos AS
    Drug Des Devel Ther; 2015; 9():2367-74. PubMed ID: 25987834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 96-well based analysis of replicon elimination with the HCV NS5A replication complex inhibitor daclatasvir.
    O'Boyle DR; Nower PT; Sun JH; Fridell R; Wang C; Valera L; Gao M
    J Virol Methods; 2013 Oct; 193(1):68-76. PubMed ID: 23684844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS].
    Gozlan Y; Mendelson E; Ben-Ari Z; Mor O
    Harefuah; 2015 Nov; 154(11):684-7, 743. PubMed ID: 26821497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options.
    Suzuki Y; Ikeda K; Suzuki F; Toyota J; Karino Y; Chayama K; Kawakami Y; Ishikawa H; Watanabe H; Hu W; Eley T; McPhee F; Hughes E; Kumada H
    J Hepatol; 2013 Apr; 58(4):655-62. PubMed ID: 23183526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.